Skip to main content
Journal cover image

Glaucoma Tube Outcomes with and without Anti-VEGF in Patients with Age-related Macular Degeneration.

Publication ,  Journal Article
Rothman, AL; Beca, FA; Tijerina, JD; Schuman, DM; Parrish, RK; Vanner, EA; Liu, KC
Published in: Ophthalmol Glaucoma
2024

PURPOSE: To compare glaucoma tube outcomes of wet age-related macular degeneration (AMD) eyes receiving anti-VEGF injections versus dry AMD eyes and no anti-VEGF. DESIGN: Retrospective clinical cohort study. PARTICIPANTS: Patients with wet AMD and a history of anti-VEGF within a year prior or after stand-alone glaucoma tube surgery and eyes with dry AMD and no history of anti-VEGF with at least 6 months of follow-up. Eyes with neovascular glaucoma or anti-VEGF for reason other than wet AMD were excluded. METHODS: A Kaplan-Meier analysis compared survival for wet versus dry AMD eyes. Failure was defined as intraocular pressure (IOP) > 21 mmHg or < 20% IOP reduction from baseline or IOP ≤ 5 mmHg for 2 consecutive postoperative visits starting at month 3, additional glaucoma surgery, or no light perception. Complete success was defined as no failure or medications at final follow-up. Hypertensive phase was defined for valved tubes as IOP > 21 mmHg within 3 months of surgery after a reduction to < 22 mmHg during the first postoperative week. Intraocular pressure, percent reduction in IOP, number of glaucoma medications, and early (< 1 year) and late (> 1 year) complications were compared through 5 years. MAIN OUTCOME MEASURES: Survival analysis, IOP, number of medications. RESULTS: Baseline IOP, number of medications, or tube type were not significantly different between wet (n = 24) and dry AMD eyes (n = 54). No wet AMD eyes failed versus 10 (18%) dry AMD eyes (P = 0.03). Five-year survival was estimated as 100% for wet AMD and 72% for dry AMD (P = 0.04). Wet AMD eyes had lower IOP (10.6 vs. 12.7 mmHg, P = 0.05), greater IOP reduction (60% vs. 49%, P = 0.04), fewer medications (1.2 vs. 2.1, P = 0.02), and more complete success (50% vs. 15%, P = 0.001) at final follow-up (32 vs. 36 months, P = 0.42). Fewer wet than dry AMD eyes experienced hypertensive phase (0/10 [0%] vs. 4/10 [40%], P = 0.04). There were no significant differences in early or late complications. CONCLUSIONS: Exposure to anti-VEGF may influence postoperative wound healing and capsule formation which may improve glaucoma tube surgical outcomes. Prospective data is needed to consider perioperative administration of anti-VEGF for glaucoma tube surgery. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

Duke Scholars

Published In

Ophthalmol Glaucoma

DOI

EISSN

2589-4196

Publication Date

2024

Volume

7

Issue

3

Start / End Page

260 / 270

Location

United States

Related Subject Headings

  • Wet Macular Degeneration
  • Visual Acuity
  • Vascular Endothelial Growth Factor A
  • Treatment Outcome
  • Retrospective Studies
  • Ranibizumab
  • Male
  • Intravitreal Injections
  • Intraocular Pressure
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Rothman, A. L., Beca, F. A., Tijerina, J. D., Schuman, D. M., Parrish, R. K., Vanner, E. A., & Liu, K. C. (2024). Glaucoma Tube Outcomes with and without Anti-VEGF in Patients with Age-related Macular Degeneration. Ophthalmol Glaucoma, 7(3), 260–270. https://doi.org/10.1016/j.ogla.2024.01.002
Rothman, Adam L., Flavius A. Beca, Jonathan D. Tijerina, Darren M. Schuman, Richard K. Parrish, Elizabeth A. Vanner, and Katy C. Liu. “Glaucoma Tube Outcomes with and without Anti-VEGF in Patients with Age-related Macular Degeneration.Ophthalmol Glaucoma 7, no. 3 (2024): 260–70. https://doi.org/10.1016/j.ogla.2024.01.002.
Rothman AL, Beca FA, Tijerina JD, Schuman DM, Parrish RK, Vanner EA, et al. Glaucoma Tube Outcomes with and without Anti-VEGF in Patients with Age-related Macular Degeneration. Ophthalmol Glaucoma. 2024;7(3):260–70.
Rothman, Adam L., et al. “Glaucoma Tube Outcomes with and without Anti-VEGF in Patients with Age-related Macular Degeneration.Ophthalmol Glaucoma, vol. 7, no. 3, 2024, pp. 260–70. Pubmed, doi:10.1016/j.ogla.2024.01.002.
Rothman AL, Beca FA, Tijerina JD, Schuman DM, Parrish RK, Vanner EA, Liu KC. Glaucoma Tube Outcomes with and without Anti-VEGF in Patients with Age-related Macular Degeneration. Ophthalmol Glaucoma. 2024;7(3):260–270.
Journal cover image

Published In

Ophthalmol Glaucoma

DOI

EISSN

2589-4196

Publication Date

2024

Volume

7

Issue

3

Start / End Page

260 / 270

Location

United States

Related Subject Headings

  • Wet Macular Degeneration
  • Visual Acuity
  • Vascular Endothelial Growth Factor A
  • Treatment Outcome
  • Retrospective Studies
  • Ranibizumab
  • Male
  • Intravitreal Injections
  • Intraocular Pressure
  • Humans